Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Regeneron Pharmaceuticals, Inc. or Vertex Pharmaceuticals Incorporated because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Regeneron Pharmaceuticals, Inc. and Vertex Pharmaceuticals Incorporated compare based on key financial metrics to determine which better meets your investment needs.

About Regeneron Pharmaceuticals, Inc. and Vertex Pharmaceuticals Incorporated

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. The company was incorporated in 1988 and is based in Tarrytown, New York.

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Latest Biotechnology and Regeneron Pharmaceuticals, Inc., Vertex Pharmaceuticals Incorporated Stock News

As of September 1, 2026, Regeneron Pharmaceuticals, Inc. had a $82.3 billion market capitalization, compared to the Biotechnology median of $282.5 million. Regeneron Pharmaceuticals, Inc.’s stock is up 10.4% in 2026, up 4.6% in the previous five trading days and up 41.87% in the past year.

Currently, Regeneron Pharmaceuticals, Inc.’s price-earnings ratio is 20.4. Regeneron Pharmaceuticals, Inc.’s trailing 12-month revenue is $15.5 billion with a 27.9% net profit margin. Year-over-year quarterly sales growth most recently was 16.7%. Analysts expect adjusted earnings to reach $53.547 per share for the current fiscal year. Regeneron Pharmaceuticals, Inc. currently has a 0.5% dividend yield.

As of September 1, 2026, Vertex Pharmaceuticals Incorporated had a $138.8 billion market cap, putting it in the 98th percentile of all stocks. Vertex Pharmaceuticals Incorporated’s stock is up 22.8% in 2026, up 1.7% in the previous five trading days and up 40.06% in the past year.

Currently, Vertex Pharmaceuticals Incorporated’s price-earnings ratio is 31.9. Vertex Pharmaceuticals Incorporated’s trailing 12-month revenue is $12.6 billion with a 35.0% net profit margin. Year-over-year quarterly sales growth most recently was 12.5%. Analysts expect adjusted earnings to reach $16.657 per share for the current fiscal year. Vertex Pharmaceuticals Incorporated does not currently pay a dividend.

How We Compare Regeneron Pharmaceuticals, Inc. and Vertex Pharmaceuticals Incorporated Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Regeneron Pharmaceuticals, Inc. and Vertex Pharmaceuticals Incorporated’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Regeneron Pharmaceuticals, Inc. and Vertex Pharmaceuticals Incorporated Stock Value Grades

Company	Ticker	Value
Regeneron Pharmaceuticals, Inc.	REGN	C
Vertex Pharmaceuticals Incorporated	VRTX	F

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Regeneron Pharmaceuticals, Inc. has a Value Score of 42, which is Average. Vertex Pharmaceuticals Incorporated has a Value Score of 14, which is Ultra Expensive.

The Value Stock Winner: No Clear Winner

Neither Regeneron Pharmaceuticals, Inc. or Vertex Pharmaceuticals Incorporated has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Regeneron Pharmaceuticals, Inc. or Vertex Pharmaceuticals Incorporated is the better investment when it comes to value.

Regeneron Pharmaceuticals, Inc. and Vertex Pharmaceuticals Incorporated Growth Grades

Company	Ticker	Growth
Regeneron Pharmaceuticals, Inc.	REGN	A
Vertex Pharmaceuticals Incorporated	VRTX	C

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Regeneron Pharmaceuticals, Inc. has a Growth Score of 82, which is Very Strong. Vertex Pharmaceuticals Incorporated has a Growth Score of 60, which is Average.

The Growth Grade Winner: Regeneron Pharmaceuticals, Inc.

As you can clearly see from the Growth Grade breakdown above, Regeneron Pharmaceuticals, Inc. has a more attractive growth grade than Vertex Pharmaceuticals Incorporated. For investors who focus solely on how a company is growing relative to other companies in the same industry, Regeneron Pharmaceuticals, Inc. could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Regeneron Pharmaceuticals, Inc. and Vertex Pharmaceuticals Incorporated’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Regeneron Pharmaceuticals, Inc.	REGN	B
Vertex Pharmaceuticals Incorporated	VRTX	D

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Regeneron Pharmaceuticals, Inc. has a Earnings Estimate Score of 67, which is Positive. Vertex Pharmaceuticals Incorporated has a Earnings Estimate Score of 23, which is Negative.

The Earnings Estimate Revisions Grade Winner: Regeneron Pharmaceuticals, Inc.

As you can clearly see from the Earnings Estimate Revisions Grade breakdown above, Regeneron Pharmaceuticals, Inc. has a better Earnings Estimate Revisions Grade than Vertex Pharmaceuticals Incorporated. For those who are specifically looking for companies with better short-term prospects when compared to other companies in the same industry, Regeneron Pharmaceuticals, Inc. could be a good stock to invest in. However, it’s important to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Regeneron Pharmaceuticals, Inc. and Vertex Pharmaceuticals Incorporated Grades

In addition to Value, Growth and Estimate Revisions, A+ Investor also provides grades for Momentum and Quality.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Regeneron Pharmaceuticals, Inc. and Vertex Pharmaceuticals Incorporated pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Regeneron Pharmaceuticals, Inc. or Vertex Pharmaceuticals Incorporated Stock?

Overall, Regeneron Pharmaceuticals, Inc. stock has a Value Score of 42, Growth Score of 82 and Estimate Revisions Score of 67.

Vertex Pharmaceuticals Incorporated stock has a Value Score of 14, Growth Score of 60 and Estimate Revisions Score of 23.

Comparing Regeneron Pharmaceuticals, Inc. and Vertex Pharmaceuticals Incorporated’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.